A pH sensing apparatus for sensing pH levels in a biological subject includes a reference needle electrode including a reference needle body and a conductive coating deposited on the reference needle body, and a sensor needle electrode including a sensor needle body, a conductive coating deposited on the sensor needle body and a sensor material deposited on a tip portion of the needle body. A measuring device is provided that is in electrical communication with the conductive coatings of the reference needle electrode and the sensor needle electrode, wherein the needle electrodes are configured to be inserted into the biological subject, and the measuring device is configured to measure an electrical signal indicative of pH levels between the reference and sensor needle electrodes.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/0538 - Measuring electrical impedance or conductance of a portion of the body invasively, e.g. using a catheter
A61B 5/1482 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means specially adapted for foetal tissue
G01N 27/30 - Electrodes, e.g. test electrodesHalf-cells
Bioactive nanoparticle compositions containing metal ions, phenolic ligands, bioactive agents, and seeding agents are provided, as are methods for their preparation. Through variation of one or more of the components of the compositions, the bioactive nanoparticles can be formulated to target specific sites in vivo, for example specific organs.
A process of producing hydrogen from air comprising: contacting a hygroscopic liquid with a source of air to absorb a water content from said source of air into the hygroscopic liquid; and electrolytically converting the water absorbed in the hygroscopic liquid into hydrogen and oxygen.
C25B 1/04 - Hydrogen or oxygen by electrolysis of water
B01D 53/14 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by absorption
An alloy includes a mixture of aluminum, tin and magnesium. An amount of the magnesium is between about 2.5% and 6.5% by weight of the mixture. The alloy is binder jet printed and liquid phase sintered.
Systems, apparatus, and methods for treating medication refractory epilepsy are disclosed. In one embodiment, a method of treating epilepsy is disclosed comprising detecting, using a first electrode array coupled to a first endovascular carrier, an electrophysiological signal of a subject. The method further comprises analyzing the electrophysiological signal using a neuromodulation unit electrically coupled to the first electrode array and stimulating an intracorporeal target of the subject using a second electrode array coupled to a second endovascular carrier implanted within a part of a bodily vessel superior to a base of the skull of the subject.
The present disclosure provides methods of regulating iron deficiency response in plants, modified plants and plant cells derived therefrom, in particular plants and plant cells with altered iron content, iron transport, iron sensing, or iron uptake.
An automated method of classifying irrigation status of fields within a geographical region includes identifying a plurality of field areas delineated by field boundaries within the geographical region. Seasonal normalised difference vegetation index (NDVI) time series data are processed to generate a plurality of aggregate field NDVI feature values for each identified field area. Irrigation status of each identified field area is classified by executing a decision tree classifier that is configured to determine a classification as either ‘irrigated’ or ‘non-irrigated’ based upon the corresponding plurality of aggregate field NDVI feature values.
G06V 10/762 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using clustering, e.g. of similar faces in social networks
G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
The present application is directed to immunomodulatory compositions comprising invariant NKT cell (iNKT cell) agonist compounds that induce expansion of tissue resident memory T-cells (Trm Cells) in combination with an immune stimulator agent that enhances an immune response to a target antigen or a polynucleotide encoding the immune stimulator. The iNKT agonists are α-GalCer analogue compounds modified at the 6 position of the galactose ring. The immune stimulator is an antigen or an mRNA encoding an antigen to create a vaccine formulation. These combinations are used in the treatment of infection or cancer in a subject, or to enrich the number of Trm cells in the liver of a subject.
A61K 31/7032 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyl-diacylglycerides, lactobionic acid, gangliosides
A61K 31/7052 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 39/015 - Hemosporidia antigens, e.g. Plasmodium antigens
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
A method of desorbing CO2 from an aqueous liquid comprising CO2, the method comprising the steps of: a) providing said aqueous liquid in the form of an aqueous colloidal solution comprising (i) a CO2 absorbent having CO2 absorbed thereto and (ii) colloidal catalyst having a core-shell structure in which the shell comprises proton-donor groups, and b) thermally desorbing CO2 from the CO2 absorbent, wherein the thermal desorption of the CO2 is catalysed by the colloidal catalyst.
B01D 53/14 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by absorption
B01J 31/04 - Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides containing carboxylic acids or their salts
THE FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH (Australia)
THE UNIVERSITY OF MELBOURNE (Australia)
Inventor
Ayton, Scott
Betrie, Ashenafi
Bush, Ashley
Lankadeva, Yugeesh
Wright, Christine
Angus, James
Abstract
Provided herein are methods for preventing or minimising hypoperfusion and hypoxia during surgery, methods for preventing, or reducing the risk of, post-operative complications associated with hypoperfusion and/or hypoxia and methods for treating and preventing vascular diseases and disorders, the methods comprising administering to subjects in need thereof, a zinc ion and at least one amino acid or a salt thereof.
OLIVIA NEWTON-JOHN CANCER RESEARCH INSTITUTE (Australia)
Inventor
Morgan, Katherine Anne
Donnelly, Paul Stephen
Wichmann, Christian Werner
Scott, Andrew Mark
Abstract
The present invention relates to compounds of formula (I) that have the ability to be used as metal complexes in radiotherapy.
The present invention relates to compounds of formula (I) that have the ability to be used as metal complexes in radiotherapy.
wherein
A is selected from the group consisting of CO2R1, and PO3R1;
B is selected from the group consisting of CO2R2, and PO3R2;
R1, R2 and R3 are each independently selected from the group consisting of H and C1-C12alkyl;
each Ra is independently selected from the group consisting of H, F, Cl, Br, I, CH3, CH2CH3, CH(CH3)2, OH, OCH3, OCH2CH3, CF3, OCF3, NO2, NH2, and CN;
each Rb is independently selected from the group consisting of H, F, Cl, Br, I, CH3, CH2CH3, CH(CH3)2, OH, OCH3, OCH2CH3, CF3, OCF3, NO2, NH2, and CN;
L is a linker having from 1 to 20 atoms in the normal chain;
or a pharmaceutically acceptable salt thereof.
The present invention relates to polymer compositions, in particular to biocompatible cross-linkable polymer compositions, methods of preparing the same and their use in the preparation of ocular implants.
15.
MULTIPLE MEASUREMENTS USING AN ELECTROCHEMICAL APTAMER-BASED SENSOR
The present disclosure relates methods of using an electrochemical aptamer- based sensor to detect and/or measure at least two parameters of a solution or suspension.
A method for offline Koopman system identification is provided which includes generating snapshots representing a thermal comfort quantification index, reshaping these snapshots into 3D tensors, and splitting them into training, validation, and testing datasets. An encoder is used to reduce state space shape, while a dynamic auxiliary network calculates the A and B matrices representing a reduced order system. The auxiliary output advances the reduced order system into a time step with the control of the boundary condition. A decoder is used to reconstruct the system to its original state for another time step, and a loss function for reconstruction, linearisation and prediction is computed.
G06F 30/28 - Design optimisation, verification or simulation using fluid dynamics, e.g. using Navier-Stokes equations or computational fluid dynamics [CFD]
According to an aspect of the present invention, there is provided a face mask, comprising: a frame defining a respiratory chamber, for receiving nose and mouth portions of a user, between a proximal end of the frame for interfacing with a face portion of the user and a distal end of the frame configured for allowing gas exchange with the environment; a vocal guide defined by a sectional portion of the frame, the guide comprising an arched nose ridge portion, side wall portions extending from the nose ridge portion and a base connecting the side wall portions, wherein the guide is configured with an inwardly-projecting contour located at one or more regions of each of the side wall portions so as to alter an output frequency response of sound waves travelling through the frame for improving speech intelligibility of the mask during use.
The present invention provides a method of forming a 3D object, the method comprising: providing a photo-curable resin, providing a print head for transmitting curing radiation to the photo-curable resin, the print head having a cavity containing gas, introducing the print 5 head into the resin to form a submerged gas-resin interface between the gas and the resin, wherein said gas-resin interface is constrained to the print head and defines a printing surface, projecting curing radiation on the submerged gas-resin interface to promote curing of the resin at the printing surface, and promoting relative movement between the gas-resin interface and the resin to produce the 3D object. The method may also include a step of 10 transmitting acoustic waves to the submerged gas-resin interface.
B29C 64/268 - Arrangements for irradiation using laser beamsArrangements for irradiation using electron beams [EB]
B29C 64/135 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using layers of liquid which are selectively solidified characterised by the energy source therefor, e.g. by global irradiation combined with a mask the energy source being concentrated, e.g. scanning lasers or focused light sources
ECochG signals are received and used to classify a state of an inner ear into an appropriate category of a plurality of categories. Each category of the plurality of categories corresponds to a respective feedback of a plurality of feedback, and a feedback of the plurality of feedback is selected and output based on the feedback corresponding to the appropriate category in which the state of the inner ear is classified, thereby indicating the specific state of the inner ear.
ST VINCENT'S HOSPITAL (MELBOURNE) LIMITED (Australia)
Inventor
Choong, Peter, Fook Meng
Duchi, Serena
Onofrillo, Carmine
Wallace, Gordon, George
Beirne, Stephen, Thomas
Gambhir, Sanjeev
Gailer, Daniel, John
Di Bella, Claudia
Abstract
An apparatus for use in preparation of a composition for treatment or repair or regeneration of tissue comprises a collection vessel configured to receive harvested tissue and at least one filter element located inside the collection vessel. The apparatus is configured to be received in a centrifuge to separate a Stromal Vascular Fraction (SVF) from the harvested tissue within the collection vessel. At least a portion or extract of the SVF separated from the harvested tissue in the apparatus is used in preparation of a treatment composition comprising a mixture of SVF or extract and a polymer composition for treatment or repair or regeneration of the tissue.
B01D 53/04 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography with stationary adsorbents
B01J 20/10 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising silica or silicate
This disclosure relates to an iontophoresis pharmaceutical delivery system comprising an array of individually addressable pharmaceutical delivery sub-systems. Each of the sub-systems comprises a delivery electrode that is insulated from electrodes of other sub-systems and a reservoir for holding the pharmaceutical to be delivered. A control circuit generates an electrical control signal and provides the electrical control signal to the delivery electrode of one the sub-systems to deliver a pharmaceutical transdermally by iontophoresis. With this array one delivery sub-system can be activated until its corresponding reservoir is depleted before activating another sub-system. Therefore, the amount of the pharmaceutical that has been delivered is known at least down to the number of reservoirs that have been depleted. Further, it is possible to simultaneously activate multiple sub-systems to increase the dose rate and to load different drug formulations into each sub-system thereby delivering multiple drugs simultaneously.
The present disclosure relates generally to lipid nanoparticles (LNPs) and compositions comprising the same, and their use in delivery of agents, such as nucleic acid-based therapeutics, in particular to transfection recalcitrant cells and/or to lung tissue.
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
A61P 11/00 - Drugs for disorders of the respiratory system
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
24.
Determining Properties of Samples Using Quantum Sensing
The Florey Institute of Neuroscience & Mental Health (Australia)
Inventor
Mccoll, Gawain
Simpson, David Allan
Hall, Liam Terres
Grant, Erin Susanne
Abstract
A method for determining one or more properties of a molecular metal ligand in a sample comprises the steps of: providing a quantum sensor: exposing the quantum sensor to the sample: applying an illumination signal to the quantum sensor for a first predetermined duration: and detecting a photoluminescence intensity emitted from the quantum sensor. A characteristic of the detected photoluminescence intensity is indicative of one of the properties of the molecular metal ligand in the sample.
G01N 33/90 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving iron binding capacity of blood
25.
METHODS FOR EVALUATING AND IMPROVING COGNITIVE FUNCTION
THE FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH (Australia)
Inventor
Boon, Wah Chin
Roessner, Ute
Pasinghe, Thusitha Wasantha Thilaka
Lei, Enie
Abstract
The present invention generally relates to method for evaluating and improving cognitive function in a subject. In particular, the invention generally relates to methods for evaluating cognitive function in a subject by determining the level of cholesteryl esters in a subject, and to improving cognitive function in a subject comprising the administration of cholesteryl oleate, or analogues thereof.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
G01N 33/92 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving lipids, e.g. cholesterol
26.
EVANESCENT FIELD RESONANCE IMAGING MICROSCOPY APPARATUS AND METHOD
A method for characterising a sample located within an imaging region, the method comprising the steps of: generating one or more evanescent fields, each associated with a direction, within the imaging region; capturing an image of the imaging region; determining one or more sample characteristics of the sample according to a spatial intensity pattern resulting from an interaction between the, or each, evanescent field and the sample within the image, and associated apparatus and system.
G01N 15/02 - Investigating particle size or size distribution
G01N 15/0227 - Investigating particle size or size distribution by optical means using imagingInvestigating particle size or size distribution by optical means using holography
Described embodiments relate to a method for predicting a toxicity of a drug to be administered to a patient. The method comprises accessing at least one computed tomography (CT) torso slice associated with the patient; using a trained artificial intelligence (AI) segmentation model to perform a labelling process of the at least one CT scan; determining at least one body composition parameter based on the at least one labelled CT slice; receiving at least one demographic parameter associated with the patient; receiving at least one dosage parameter associated with the drug to be administered to the patient; and using a trained AI prediction model, generating an output based on the at least one body composition parameter, the at least one demographic parameter and the at least one dosage parameter, the output corresponding to a predicted toxicity of the drug to the patient.
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
A61B 6/00 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment
G06V 10/26 - Segmentation of patterns in the image fieldCutting or merging of image elements to establish the pattern region, e.g. clustering-based techniquesDetection of occlusion
G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
The present disclosure relates to methods for imaging biological ssue over me, and uses of the imaging methods. It relates par cularly but not exclusively to imaging of live biological ssue, such as corneal or re nal ssue of a subject and allows for the dynamic (temporal) tracking of immune cells in the biological ssue.
The present invention relates to cells and methods for studying complex human traits such as diseases and drag responses. The invention relates to cell culture methods involving differentiated cells, in particular from multiple human-induced pluripotent stem cell lines (hiPSC), for population-scale experiments, for example, population genomics of gene regulation.
The invention provides a gas separation membrane comprising: a glassy polymeric matrix; and a metal complex dispersed in the glassy polymeric matrix, the metal complex comprising a polydentate ligand coordinated to a metal selected from the group 10-14, period 4-6 elements, wherein the metal complex selectively enhances the permeability of carbon monoxide through the gas separation membrane.
B01D 53/22 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by diffusion
A method of producing transition metal oxide particles that display insulator-to-metal transition (IMT), the method comprising the steps of a) hydrothermally reducing a transition metal oxide precursor to produce amorphous transition metal oxide hydrate particles, and b) annealing said amorphous transition metal oxide hydrate particles to produce crystalline transition metal oxide particles.
B82Y 20/00 - Nanooptics, e.g. quantum optics or photonic crystals
B82Y 40/00 - Manufacture or treatment of nanostructures
G02B 6/12 - Light guidesStructural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type of the integrated circuit kind
G02B 6/122 - Basic optical elements, e.g. light-guiding paths
The present invention provides a method of producing a battery-grade precursor solution for production of a cathode material, the method comprising the steps of: providing a battery black-mass liquid leachate, said liquid leachate comprising one or more battery metals; adding an immiscible liquid solvent to said liquid leachate and performing liquid-liquid extraction to load said liquid solvent with the one or more battery metals; and subjecting the resulting loaded liquid solvent to stripping in at least one stripping unit; wherein stripping is performed using an aqueous stripping solution having a pH that extracts the one or more battery metals into the aqueous stripping solution to provide for said battery-grade precursor solution.
The present invention relates to nanocomplexes (NCs) comprising a polysaccharide nanoparticle (NP) and a hormone selected from insulin, glucagon, or glucagon-like protein-1, and uses thereof for reducing the blood glucose level, in particular, for the treatment of diabetes.
A61K 47/61 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
The invention provides for the use of a brittle silica containing particulate material sand substitute selected from the group including vortex-processed glass fines (VGF), vortex apparatus processed desert sand (VDS), and vortex-processed pond ash (VPPA) to at least partially substitute sand in a cement composition or products thereof.
A metamaterial force sensor, the sensor comprising: one or more metamaterial modules, each module comprising a plurality of mechanical unit cells operatively interconnected to allow force transmission therethrough; a transducer operatively coupled to the or each module, the transducer being configured to output a signal corresponding to a displacement of the or each module in response to a force transmission, wherein each of the mechanical unit cells provides a predetermined range of displacement, based on preconfigured structural parameters of said unit cell, in response to force transmissions, and wherein at least two of the mechanical unit cells of the or each module are configured with different predetermined ranges of displacement in response to force transmissions resulting in multiple sensitivity regimes.
G01L 5/169 - Apparatus for, or methods of, measuring force, work, mechanical power, or torque, specially adapted for specific purposes for measuring several components of force using magnetic means
B32B 3/12 - Layered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shapeLayered products comprising a layer having particular features of form characterised by a discontinuous layer, i.e. apertured or formed of separate pieces of material characterised by a layer of regularly-arranged cells whether integral or formed individually or by conjunction of separate strips, e.g. honeycomb structure
G01L 1/04 - Measuring force or stress, in general by measuring elastic deformation of gauges, e.g. of springs
The present disclosure relates generally to methods for the treatment of cancer with an immune checkpoint inhibitor. The present disclosure further relates to methods for the stratification of patients with cancer for treatment with an immune checkpoint inhibitor, and kits comprising one or more reagents or devices for use in performing the methods disclosed herein.
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 35/04 - Antineoplastic agents specific for metastasis
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Royal Melbourne Institute of Technology (Australia)
Inventor
Simpson, David Allan
Dontschuk, Nikolai
Mccloskey, Daniel James
Stacey, Alastair Douglas
Abstract
This disclosure relates to an electrical field sensor. The sensor comprises a diamond substrate with a conducting surface providing positive charge carriers and multiple defects disposed in the diamond substrate. The sensor further comprises an optical apparatus to initialise and readout the multiple defect vacancies to determine the electrical field based on a detected fluorescence of the multiple defects. The multiple defects are located at a depth below the surface to enable the positive charge carriers to reach and positively charge the multiple defect vacancies under an influence of an external negative electric field to thereby alter the fluorescence of at least some of the multiple defects. Since the fluorescence can be measured optically, no electrical connections or amplifiers are required on the surface, which means significantly higher densities of sensors can be implemented.
Devices, methods and systems for transmitting signals through a device located in a blood vessel of an animal, for stimulating and/or sensing activity of media proximal to the device, wherein the media includes tissue and/or fluid.
A61B 5/291 - Bioelectric electrodes therefor specially adapted for particular uses for electroencephalography [EEG]
A61F 2/88 - Stents in a form characterised by wire-like elementsStents in a form characterised by a net-like or mesh-like structure the wire-like elements formed as helical or spiral coils
A61F 2/90 - Stents in a form characterised by wire-like elementsStents in a form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
40.
IDENTIFICATION OF CONTACT LENS WEARERS PREDISPOSED TO CONTACT LENS DISCOMFORT
The present disclosure relates to methods for identifying contact lens wearers predisposed to contact lens discomfort based on basal tear level of one or more of interleukins.
The present disclosure relates generally to a polynucleotide construct comprising a Felid alphaherpesvirus 1 (FeHV-1) genome modified by insertion of one or more nucleic acid sequences into a non-coding region between two convergent FeHV-1 genes of the FeHV- 1 genome, wherein the one or more nucleic acid sequences encode for one or more feline reproductive protein antigens; capable of stimulating an immune response to reduce the occurrence of a pregnancy, and uses thereof.
Mycoplasma bovis infection in cattle is a major production limiting disease of cows and calves. M. bovis can cause a range of conditions in cattle. including mastitis in dairy cows. arthritis in cows and calves. pneumonia in calves, and various other diseases including late-term abortion. The present invention provides methods for detecting multiple anti-M. bovis antibodies in a single multiplex immunoassay.
The present invention relates to pharmaceutical combinations for treating or preventing insulin resistance and associated disorders, in particular the use combinations comprising a 4-epimerase inhibitor and a GLP-1 receptor agonist for treating or preventing insulin resistance and associating disorders such as obesity and type-2 diabetes, supressing appetite and/or promoting weight loss.
A61K 31/7008 - Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
For constructing an asymmetric RF pulse for an MRI system, a first RF amplitude for a first part of a time interval is determined and an RF amplitude curve, which depends on at least one RF curve parameter is received. A combined RF amplitude curve for the time interval is determined by combining the first RF amplitude for the first part of the time interval and the RF amplitude curve for a second part of the time interval, which succeeds the first part of the time interval. The combined RF amplitude curve is optimized using a loss function, which comprises an energy loss term, which depends on a pulse energy of the combined RF amplitude curve, and using the at least one RF curve parameter as at least one optimization variable. A combined amplitude of the asymmetric RF pulse is given by the optimized combined RF amplitude curve.
Provided herein are implantable electroceutical devices. In some embodiments, an implantable electroceutical device includes a gastric motility sub assembly configured to record gastric myoelectric activity and gastric contraction activity in a subject when the implantable electroceutical device is operably implanted in the subject. In some embodiments, an implantable electroceutical device also includes a gastric electrical stimulation (GES) sub-assembly configured to electrically stimulate a nervous system of a subject when the implantable electroceutical device is operably implanted in the subject. Related implantable electroceutical devices, systems, methods, kits, and computer readable media are also provided.
Grains Research and Development Corporation (Australia)
Inventor
Haites, Ruth Elizabeth
Jacobe, Helen
Abstract
The present disclosure relates to compositions and methods for inducing encystment of and/or stabilising ciliate cells. In particular, the present disclosure relates to polymers and polymeric solutions, including hydrocolloids, which may be used to induce encystment of trophont ciliate cells to form encysted ciliate cells and/or stabilise encysted cells. The present disclosure also relates to methods of infecting and/or colonising molluscs with the compositions and ciliates described herein.
A01N 63/00 - Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
This disclosure relates to a method for detecting an attack on a machine learning system. A classical neural network comprises a first output indicative of a first classification by the classical neural network and a quantum neural network comprises a second output indicative of a second classification of the input data by the quantum neural network. The method comprises comparing the first output to the second output; and responsive to the first output being different to the second output, generating an indication that an attack is detected.
G06F 21/55 - Detecting local intrusion or implementing counter-measures
G06F 21/54 - Monitoring users, programs or devices to maintain the integrity of platforms, e.g. of processors, firmware or operating systems during program execution, e.g. stack integrity, buffer overflow or preventing unwanted data erasure by adding security routines or objects to programs
G06F 21/57 - Certifying or maintaining trusted computer platforms, e.g. secure boots or power-downs, version controls, system software checks, secure updates or assessing vulnerabilities
A method comprising: receiving, by a fuzzing module of a computing device, data, the data being existing data for input into an application for testing; modifying, by the fuzzing module, the existing data to generate test data; communicating the existing data and the test data to the application to determine whether there is a change in an output associated with the application; when it is determined that there is no change, identify any excessive data exposure in one or more code paths of the application; and providing a notification of any excessive data exposure identified.
G06F 21/57 - Certifying or maintaining trusted computer platforms, e.g. secure boots or power-downs, version controls, system software checks, secure updates or assessing vulnerabilities
The present invention relates to methods of treating or preventing insulin resistance and associated disorders, in particular the use of 4-epimerase inhibitors for treating or preventing insulin resistance and associating disorders, such as obesity and type-2 diabetes.
The present disclosure relates to use of tear fluid neuropeptide Y (NPY) level for diagnosis, prognosis, assessment and therapy stratification of corneal nerve damage or loss, corneal neuropathy, corneal neuropathic pain, corneal neuralgia, ocular disease, or peripheral neuropathy.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
51.
SYSTEM AND METHOD OF CONTROLLING WATER EVAPORATION
COTTON RESEARCH AND DEVELOPMENT CORPORATION (Australia)
Inventor
Lee, Junghoon
Scofield, Joel, Mathew, Paul
Qiao, Greg, Guanghua
Monty, Jason, Patrick
Gurr, Paul, Andrew
Western, Andrew William
Abstract
A water evaporation mitigation system configured to control evaporation from a body of water having a water surface, the system comprising: at least one wind barrier that includes at least one wind suppression panel extending outwardly from the water surface and substantially around a perimeter of a selected surface area of the body of water, wherein the at least one wind suppression panel is formed from a mesh material having an optical porosity of from 5 to 65%.
A piezoelectric surgical tool tip 10, comprising a tool tip body 20 having a proximal end 22 configured for connection with a tool handle 32 of a powered piezoelectric surgery unit 30 and a distal end 24 configured for cutting into an alveolar bone 34 of a patient using micro- vibrations generated by the surgery unit 30 and tool handle 32, the distal end 24 comprising an outwardly extending arm 26 and a base 40 on which extends a plurality of cutting projections 42 arranged in the form of an array 44, wherein the base 40 is mounted substantially perpendicular to the arm 26 and the array 44 is substantially rectangular in shape with a maximum width of about 6 mm and a maximum length of about 5 mm.
Devices, methods and systems for transmitting signals through a device located in a blood vessel of an animal, for stimulating and/or sensing activity of media proximal to the device, wherein the media includes tissue and/or fluid.
A61B 5/291 - Bioelectric electrodes therefor specially adapted for particular uses for electroencephalography [EEG]
A61F 2/90 - Stents in a form characterised by wire-like elementsStents in a form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
A sample analysis method, comprising: obtaining a multispectral image (e.g., a thermal multi spectral image) of a first sample of a sample class, having a first number of component images, each component image associated with a unique spectral band and representing, at each pixel of the particular component image, an intensity of incident radiation, wherein the spectral band of each component image overlaps in part with at least one spectral band of another component image; and applying a sample image analyser to said multispectral image, wherein the sample image analyser implements a pretrained machine learning algorithm configured to generate a reconstructed spectrum comprising a second number of spectral points, wherein the second number is larger than the first number, wherein the first number is two or greater, and wherein the unique spectral bands are arranged to cover an operating band of the long-infrared spectrum, and related device and system.
Processes for the synthesis of [8944 from [8944]4-salt are provided. The [8944 can be reacted with biomarker targeting agents to produce 89Zr labelled radiopharmaceuticals. The 89Zr labelled radiopharmaceuticals find use in, for example, non-invasive molecular imaging.
C05G 3/90 - Mixtures of one or more fertilisers with additives not having a specifically fertilising activity for affecting the nitrification of ammonium compounds or urea in the soil
The present invention relates to compositions for mineralizing a dental surface, in particular tooth enamel. Methods of mineralizing hypomineralized lesions (including subsurface lesions) in the tooth enamel caused by dental caries, dental corrosion and fluorosis are also provided. In particular, the invention relates to a method of mineralizing a dental surface or subsurface comprising contacting the dental surface or subsurface with a compound that is capable of increasing or maintaining the pH of a solution and a mineralizing agent.
The present invention relates to compositions and their use for oral care. In particular, the compositions and methods are for maintaining oral health and/or treating various oral conditions such as gingivitis. The present invention relates to methods and uses of stabilized amorphous calcium phosphate (ACP) and/or stabilized amorphous calcium fluoride phosphate (ACFP) in the preparation of a medicament for reducing pathogenic oral bacteria at an oral site in an individual; increasing commensal oral bacteria at an oral site in an individual; decreasing the proportion of pathogenic oral bacteria at an oral site in an individual; inhibiting oral dysbiosis; reducing gingival inflammation in an individual in need thereof; treating gingivitis in an individual in need thereof; and treating chronic gingivitis in an individual in need thereof.
A61K 9/68 - Medicinal preparations characterised by special physical form chewing gum type
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
59.
FLUORIDE COMPOSITION AND METHODS FOR DENTAL MINERALIZATION
The present invention relates to compositions and methods for mineralizing a dental surface or subsurface including providing a composition including stabilized ACP and a source of fluoride ions.
The present invention relates to the determination of menstrual cycle time point based on endometrial gene expression profile. In one embodiment, the present invention relates to the generation of endometrial gene expression profiles from an endometrial sample and the assignment of the sample to a menstrual cycle stage.
C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
The present invention relates to improved complexes of amorphous calcium phosphate and/or amorphous calcium fluoride phosphate stabilised by phosphopeptides/phosphoproteins by addition of stannous ions. These complexes have anticariogenic properties useful to protect tooth structures as they remineralize (repair) early stages of dental caries and have other dental/medical applications (including anti-calculus, anti-erosion/corrosion and anti-dentinal hypersensitivity). Methods of making the complexes of the invention and of treatment or prevention of various dental conditions including dental caries, dental calculus, dental erosion/corrosion and dental hypersensitivity are also provided.
A method for text mining from one or more tables is provided. The method includes the steps of: receiving one or more tables, the tables having one or more table labels, and one or more cells to be processed, transforming each of the cells into cell vector representations; encoding the one or more cell vector representations with a sequential 2D model; obtaining one or more table-level vector representations by summarising the semantics of the cell vector representations by an image classification model; and mapping the output of to an output vector which represents the probability of each of the table labels.
G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
G06N 3/0442 - Recurrent networks, e.g. Hopfield networks characterised by memory or gating, e.g. long short-term memory [LSTM] or gated recurrent units [GRU]
63.
ELECTRICAL TECHNIQUES FOR PREDICTIVE METHODS AND RELATED TREATMENTS OF A COCHLEA
A method, comprising obtaining data based on impedance values within a cochlea of a human at a first temporal location and at a second temporal location after the first temporal location, evaluating the obtained data and implementing a treatment based on the evaluation. In an embodiment, the treatment implemented is a steroid treatment.
FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH (Australia)
DEAKIN UNIVERSITY (Australia)
Inventor
Nisbet, David Russell
Jackson, Colin John
Parish, Clare Louise
Williams, Richard James
Abstract
The present invention relates to biocompatible hydrogels, in particular, biocompatible hydrogels for delivering a cell to a subject, wherein the hydrogel comprising a scaffold and an oxygen carrier.
Yissum Research Development Company of the Hebrew University of Jerusalem (Israel)
Inventor
Morokoff, Andrew
Kaye, Andrew H.
Jones, Jordan
Siegal, Tali
Abstract
The present invention relates to methods of detecting and/or diagnosing brain cancer in a subject based upon expression levels of microRNA. The present invention also provides methods of monitoring tumour burden and/or determining tumour regression in a subject suffering from brain cancer and monitoring progression of brain cancer in a subject.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
The invention relates to (i) a photovoltaic cell, comprising: an absorber layer comprising a perovskite material; and an ultrathin hole-transport layer; (ii) a photovoltaic cell comprising an absorber layer comprising perovskite material, a 5 hole transport layer and a protective layer located between the absorber layer and the hole transport layer, the protective layer having a valence band with an energy level that is between the energy levels of the valence bands of the absorber layer and the hole transport layer; and (iii) a photovoltaic cell comprising a barrier layer located between inner cell layers and an electrode and configured to suppress 0 diffusion of metal from the electrode into the inner layers. Also disclosed are methods of fabricating said photovoltaic cells and methods of fabricating a doped precursor for use in fabricating a photovoltaic cell.
H01L 31/0392 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by their semiconductor bodies characterised by their crystalline structure or particular orientation of the crystalline planes including thin films deposited on metallic or insulating substrates
H01L 31/0725 - Multiple junction or tandem solar cells
H01L 31/18 - Processes or apparatus specially adapted for the manufacture or treatment of these devices or of parts thereof
H10K 30/57 - Photovoltaic [PV] devices comprising multiple junctions, e.g. tandem PV cells
H10K 71/12 - Deposition of organic active material using liquid deposition, e.g. spin coating
H10K 85/50 - Organic perovskitesHybrid organic-inorganic perovskites [HOIP], e.g. CH3NH3PbI3
67.
Methods, systems, and apparatus for closed-loop neuromodulation
Systems, apparatus, and methods for treating medication refractory epilepsy are disclosed. In one embodiment, a method of treating epilepsy is disclosed comprising detecting, using a first electrode array coupled to a first endovascular carrier, an electrophysiological signal of a subject. The method further comprises analyzing the electrophysiological signal using a neuromodulation unit electrically coupled to the first electrode array and stimulating an intracorporeal target of the subject using a second electrode array coupled to a second endovascular carrier implanted within a part of a bodily vessel superior to a base of the skull of the subject.
The present invention relates to compounds and methods for the targeted delivery of diagnostic/therapeutic radionuclides to cancer tissue. In particular, the present invention relates to the targeted delivery of diagnostic/therapeutic radionuclides to cholecystokinin-2 receptor positive cancers and to methods for the diagnosis and treatment of cancer.
The present invention relates to compounds and methods for the targeted delivery of diagnostic/therapeutic radionuclides to cancer tissue. In particular, the present invention relates to the targeted delivery of diagnostic/therapeutic radionuclides to cholecystokinin-2 receptor positive cancers and to methods for the diagnosis and treatment of cancer.
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Medical devices used in ocular surgery; surgical instruments; surgical implantation devices used in corneal transplant surgery; hydrogel film in the nature of ocular implants made of artificial materials combined with human tissue for medical purposes, namely, ocular surgery, intra-ocular surgery, and corneal transplants Medical services; ocular surgical services; medical treatment services; surgical treatment services, namely, corneal transplant and repair procedures; surgical procedures in the nature of ocular surgery; treatment of disease, namely, treatment of eye diseases and conditions
The invention relates to antigen binding sites, antibodies and fragments thereof, as well as compositions, kits and uses thereof for the treatment, attenuation and/or prevention of human immunodeficiency virus type 1 (HIV-1).
Centre for Eye Research Australia Limited (Australia)
The University of Melbourne (Australia)
Heriot Eyecare Pty. Ltd. (Australia)
Inventor
Heriot, Wilson J.
Bui, Bang Viet
Metha, Andrew Bernard
Abstract
A method of integrating or fusing at least a part of a retina and at least one of a retinal pigmented epithelium (RPE) and choroid underlying the retina and the RPE is disclosed. The method comprises photodehydrating at least some proximal fluid separating one or more of the retina, the RPE and the underlying choroid, with photodehydrating laser light to thereby allow direct contact between the retina and at least one or more of the RPE and choroid. The method further comprises drying at least some of the proximal fluid with a gas flowing at a rate of up to 200 ml/min and photocoagulating with photocoagulating laser light to thereby integrate or fuse at least part of the retina with one or both of the RPE and choroid. Also provided are a device and a system for integrating or fusing these tissues.
This disclosure relates to a method for estimating a solution to a problem represented by a Hamiltonian on a quantum computer having a quantum state. A classical computer determines a trial state and evolves the quantum state of the quantum computer based on the trial state. The computer then determines estimates for expectation values with respect to the trial state of powers of the Hamiltonian based on measurements from the quantum computer and calculates an estimate of the solution based on the estimates for the expectation values of powers of the Hamiltonian for the trial state. The computer then repeated updates the trial state and repeats the measuring steps to iteratively improve the estimate of the solution.
The present invention relates to novel prime-boost and heterologous boost regimens for immunisation against coronavirus infections. The method involves immunization of a subject or increasing an immune response of a subject previously exposed to coronavirus, comprising administering a therapeutically effective amount of a vaccine comprising a coronavirus spike receptor binding domain (RBD) antigen or a nucleic acid encoding the RBD antigen.
OLIVIA NEWTON-JOHN CANCER RESEARCH INSTITUTE (Australia)
Inventor
Wichmann, Christian Werner
Rudd, Stacey Erin
Scott, Andrew Mark
Donnelly, Paul Stephen
Abstract
Processes for the synthesis of zirconium-89 radiolabelled biological polymer-chelate agent conjugates are provided. Radiolabelling is performed in the presence of a polycarboxylate buffer resulting in improved reaction kinetics and short process times. The processes provide a high degree of reproducibility, excellent radiochemical yields and may be automated.
A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
G01N 33/534 - Production of labelled immunochemicals with radioactive label
THE FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH (Australia)
THE UNIVERSITY OF MELBOURNE (Australia)
Inventor
Wade, John Desmond
Li, Wenyi
Abstract
Disclosed are proteinaceous molecule dimers represented by Formula I, methods for preparing the proteinaceous molecule dimers and methods of use thereof. More specifically, this invention relates to dimers of antimicrobial peptides represented by Formula I, methods for preparing the dimers of antimicrobial peptides and methods of treating an infection, inflammatory disorder and autoimmune disorder, eliciting or enhancing an immune response and disrupting a biofilm. Also provided are bifunctional linkers used in the preparation of the proteinaceous molecule dimers.
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
The present invention relates to mRNA, mRNA compositions, kits and uses thereof for the treatment of lysosomal storage diseases. In one aspect, the present invention relates to the treatment of Niemann-Pick type C disease.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61K 31/7115 - Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Computer software for calculating the risk of disease;
computer software for detecting disease; computer software
for detecting kidney disease; computer software for health
and disease prognoses; computer software for estimating and
detecting kidney failure; computer software for estimating
kidney filtering efficacy; artificial neural network
software; data processing software; data analysis software. Design and development of software; design and development
of an online calculator for detection of disease; software
as a service (SaaS); platform as a service (PaaS); provision
of online non-downloadable software for calculating the risk
of disease; provision of online non-downloadable software
for detecting disease; provision of online non-downloadable
software for health and disease prognoses; provision of
online non-downloadable software for detecting kidney
disease; provision of online non-downloadable software for
estimating and detecting kidney failure; provision of online
non-downloadable software for estimating kidney filtering
efficacy; provision on online non-downloadable artificial
neural network software; provision of online
non-downloadable data processing software; provision of
online non-downloadable data analysis software; medical
research; conducting clinical trials; advisory, consultancy
and information services relating to the aforesaid. Provision of health information via an online health
calculator; provision of medical services via an online
health assessment and prognoses tool; health care services;
health assessment services; health diagnosis services;
medical and disease diagnostic services (analysis); health
care namely diagnosis, prevention, treatment of disease;
health care namely diagnosis, prevention, treatment of
diabetes; health care namely diagnosis, prevention,
treatment of complications associated with disease; health
care namely diagnosis, prevention, treatment of
complications associated with diabetes; advisory,
consultancy and information services relating to the
aforesaid.
The present application is directed to immunomodulatory compositions comprising invariant NKT cell (iNKT cell) agonist compounds that induce expansion of tissue resident memory T-cells (Trm Cells) in combination with an immune stimulator agent that enhances an immune response to a target antigen or a polynucleotide encoding the immune stimulator. The iNKT agonists are a-GalCer analogue compounds modified at the 6 position of the galactose ring. The immune stimulator is an antigen or an mRNA encoding an antigen to create a vaccine formulation. These combinations are used in the treatment of infection or cancer in a subject, or to enrich the number of Trm cells in the liver of a subject.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Central Adelaide Local Health Network Incorporated (Australia)
Inventor
Heron, Sarah Elizabeth
Dibbens, Leanne Michelle
Berkovic, Samuel Frank
Scheffer, Ingrid Eileen
Mulley, John Charles
Abstract
The present invention related to the proline rich transmembrane protein 2 (PRRT2) gene, and the identification of mutations and variations in PRRT2 that give rise to seizure and movement disorders. Accordingly, the present invention provides methods for the diagnosis or prognosis of such disorders by identifying alterations in the PRRT2 gene. Identification of alterations in the PRRT2 gene also enables the identification of subjects with an increased likelihood of having an offspring predisposed to such disorders. The present invention also provides an isolated nucleic acid molecule comprising an alteration in the PRRT2 gene, wherein said alteration produces a seizure and/or movement disorder phenotype. Also provided is an isolated PRRT2 polypeptide that comprises an alteration which produces a seizure and/or movement disorder phenotype. Furthermore, the present invention provides kit for diagnosing or prognosing a seizure and/or movement disorder in a subject, or for identifying a subject with an increased likelihood of having an offspring predisposed to a seizure and/or movement disorder, wherein the kit includes one or more components for testing for the presence of an alteration in the PRRT2 gene in the subject.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
An automated method of classifying irrigation status of fields within a geographical region comprises identifying a plurality of field areas (500) delineated by field boundaries within the geographical region. Seasonal normalised difference vegetation index (NDVI) time series data (604) are processed (612) to generate a plurality of aggregate field NDVI feature values for each identified field area. Irrigation status of each identified field area is classified (620) by executing a decision tree classifier that is configured to determine a classification as either 'irrigated' or 'non-irrigated' based upon the corresponding plurality of aggregate field NDVI feature values.
G06V 10/26 - Segmentation of patterns in the image fieldCutting or merging of image elements to establish the pattern region, e.g. clustering-based techniquesDetection of occlusion
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
The present disclosure relates to modified butyrophilin 2A and 3A, and butyrophilin 2A-3A complexes and use thereof to induce or enhance TCR activation.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
ST VINCENT'S HOSPITAL (MELBOURNE) LIMITED (Australia)
UNIVERSITY OF WOLLONGONG (Australia)
SWINBURNE UNIVERSITY OF TECHNOLOGY (Australia)
THE UNIVERSITY OF MELBOURNE (Australia)
Inventor
Choong, Peter, F.M.
Gambhir, Sanjeev
Wallace, Gordon, George
Duchi, Serena
Onofrillo, Carmine
O’connell, Cathal, D.
Di Bella, Claudia
Moulton, Simon, Edward
Abstract
A functionalised polymer comprising a polymer partially functionalised with: a plurality of photocrosslinkable moieties linked to the polymer, each photocrosslinkable moiety comprising a reactive functionality capable of photocrosslinking; and a plurality of cell adhesion moieties each linked to the polymer via a linker, each cell adhesion moiety comprising a cell adhesion motif, and wherein the functionalised polymer further comprises a plurality of functional groups capable of ionic crosslinking with an ionic crosslinking agent. A method for forming a liquified polymer composition comprising cells from a tissue sample, the method comprising: providing a tissue sample comprising cells; contacting the sample with the functionalised polymer in binding conditions, said binding conditions being conditions that enable binding of cells in the sample to the functionalised polymer, so that said cells are bound to the functionalised polymer; culturing the cells bound to the polymer under conditions and for a time that allows the cell number to increase; providing conditions to induce a solid to liquid phase change of the functionalised polymer; thereby forming a liquified polymer composition comprising cells from a tissue sample.
The present technology provides compounds, as well as compositions including such compounds, useful for imaging and/or treatment of a non-small cell lung cancer, small cell carcinoma of the lung, bladder cancer, colon cancer, gallbladder cancer, pancreatic cancer, esophageal cancer, melanoma, liver cancer, primary gastric adenocarcinoma, primary colorectal adenocarcinoma, renal cell carcinoma, prostate cancer, a neuroendocrine tumor, a pituitary tumor, a vasoactive intestinal peptide-secreting tumor, a glioma, breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, and/or a metastatic cancer. The compounds include a tumor targeting domain (that includes a moiety capable of recognizing or interacting with a molecular target on the surface of tumor cells), a blood-protein binding domain, and a sarcophagine-containing domain, where the moiety of the tumor targeting domain is distal to and sterically unimpeded by the blood-protein binding domain.
B01D 53/14 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by absorption
B01J 31/02 - Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
B01J 31/04 - Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides containing carboxylic acids or their salts
A portable isolation unit for use with a bed or chair, including an enclosure portion configurable between a stowed state and a deployed state, in which the enclosure portion substantially shields over an end of the bed or chair; a ventilation unit configured for applying air pressure to an area beneath the enclosure portion when the enclosure portion is in the deployed state; and a portable frame to which the enclosure portion and ventilation unit are mounted.
A61G 10/02 - Treatment rooms for medical purposes with artificial climateTreatment rooms for medical purposes with means to maintain a desired pressure, e.g. for germ-free rooms
The present disclosure relates to improved supraparticles loaded with high levels of payload and methods for their production. Such supraparticles may be used in a range of therapeutic applications, for example, to improve growth or survival of cells and/or treat disease.
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
The invention provides a rotor for a peristaltic pump, the rotor comprising a body for rotation about an axis, the body having a first side and a second side, the body supporting a plurality of spaced first rollers extending from the body on the first side, the first rollers positioned at a first common radius from the axis, the body further supporting a plurality of spaced second rollers extending from the body on the second side, the second rollers positioned at a second common radius from the axis. The invention extends to a peristaltic pumping unit comprising such a rotor assembled with a first stator and a second stator, the first stator having one or more compressible fluid channels arranged to be compressed by said first rollers and the second stator having one or more compressible fluid channels arranged to be compressed by said second rollers. The invention also concerns a stator for a peristaltic pump, having a body with a planar surface and two or more fluid channels, each fluid channel having a compressible arcuate portion on or in the planar surface of the stator, the arcuate portions arranged to be compressed by a plurality of rollers mounted on a rotor, the arcuate portions each connecting to further portions of the fluid channel extending in a direction away from the planar surface such that the fluid channels take a three dimensional path within the body of the stator.
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Downloadable computer software for calculating the risk of disease; Downloadable computer software for analyzing health data for detecting disease; Downloadable computer software for analyzing health data for detecting kidney disease; Downloadable computer software for analyzing health data for health and disease prognoses; Downloadable computer software for analyzing health data for estimating and detecting kidney failure; Downloadable computer software for analyzing health data for estimating kidney filtering efficacy; Downloadable artificial neural network software for analyzing health data for detecting diseases, estimating kidney failure, estimating kidney filtering efficacy, and calculating the risk of disease; Downloadable data processing software; Downloadable data analysis software Design and development of software; Design and development of computer software featuring an online calculator for detection of disease; Software as a service (SaaS) services featuring computer software for analyzing health data for detecting diseases, estimating kidney failure, estimating kidney filtering efficacy, and calculating the risk of disease; Platform as a service (PaaS) services featuring computer software platforms for analyzing health data for detecting diseases, estimating kidney failure, estimating kidney filtering efficacy, and calculating the risk of disease; Provision of online non-downloadable software for calculating the risk of disease; Provision of online non-downloadable software for analyzing health data for detecting disease; Provision of online non-downloadable software for analyzing health data for health and disease prognoses; Provision of online non-downloadable software for analyzing health data for detecting kidney disease; Provision of online non-downloadable software for analyzing health data for estimating and detecting kidney failure; Provision of online non-downloadable software for analyzing health data for estimating kidney filtering efficacy; Provision of online non-downloadable artificial neural network software for analyzing health data for detecting diseases, estimating kidney failure, estimating kidney filtering efficacy, and calculating the risk of disease; Provision of online non-downloadable data processing software; Provision of online non-downloadable data analysis software; Medical research; Conducting medical and scientific research in the field of clinical trials; Advisory, consultancy, and information services relating to the aforesaid, namely, advisory services relating to computer software and providing information about medical research Provision of health information via an online health calculator; Medical and disease diagnostic services, namely, performing diagnosis of diseases; Health care services; Health diagnosis services, namely, performing diagnosis of diseases and performing diagnosis of risk of diseases; Health care, namely, diagnosis, prevention, treatment of disease; Health care, namely, diagnosis, prevention, treatment of diabetes; Health care, namely, diagnosis, prevention, treatment of complications associated with disease; Health care, namely, diagnosis, prevention, treatment of complications associated with diabetes; Advisory, consultancy and information services relating to the aforesaid, namely, medical advisory services, medical consultations and medical information
A small-sized, portable enclosure protects a gas sensor against degradation due to environmental exposure and changes in atmospheric conditions. The protective enclosure includes an inlet for introduction of a gas into the enclosure, an outlet for release of the gas upon completion of a sensing run, and at least one retractable filter that removes from the inflowing gas deleterious compounds that can compromise the integrity of the sensor or cause the sensor to degrade over time. The enclosure does not include any filters during the measurement phase of the sensing run in order to allow the gas sensor to accurately measure an unmodified gas mixture and/or analyte.
G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups
G01N 27/12 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance of a solid body in dependence upon absorption of a fluidInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance of a solid body in dependence upon reaction with a fluid
A blood collection device comprising a dispenser part having a plurality of independent outlet fluid passages, each terminating at a respective outlet port for coupling with a detachable storage container; and a receiver part having an inlet fluid passage associated with an inlet port for coupling with a blood transfer tube, the receiver part being operatively coupled with, and moveable relative to, the dispenser part so that the inlet fluid passage is moveable to align with any one of the outlet fluid passages to form a connected fluid pathway therebetween.
OLIVIA NEWTON-JOHN CANCER RESEARCH INSTITUTE (Australia)
Inventor
Morgan, Katherine, Anne
Donnelly, Paul, Stephen
Wichmann, Christian, Werner
Scott, Andrew, Mark
Abstract
22R133R122R233R2; R1, R2and R311212alkyl; each Ra3233232333222, and CN; each Rb3233232333222, and CN; L is a linker having from 1 to 20 atoms in the normal chain; or a pharmaceutically acceptable salt thereof.
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
OLIVIA NEWTON-JOHN CANCER RESEARCH INSTITUTE (Australia)
Inventor
Morgan, Katherine Anne
Donnelly, Paul Stephen
Wichmann, Christian Werner
Scott, Andrew Mark
Abstract
The present invention relates to compounds of formula (I) that have the ability to be used as metal complexes in radiotherapy. Formula (I) wherein A is selected from the group consisting of CO2R1, and PO3R1; B is selected from the group consisting of CO2R2, and PO3R2; R1, R2 and R3 are each independently selected from the group consisting of H and C1-C12alkyl; each Ra is independently selected from the group consisting of H, F, Cl, Br, I, CH3, CH2CH3, CH(CH3)2, OH, OCH3, OCH2CH3, CF3, OCF3, NO2, NH2, and CN; each Rb is independently selected from the group consisting of H, F, Cl, Br, I, CH3, CH2CH3, CH(CH3)2, OH, OCH3, OCH2CH3, CF3, OCF3, NO2, NH2, and CN; L is a linker having from 1 to 20 atoms in the normal chain; or a pharmaceutically acceptable salt thereof.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
Embodiments generally relate to a method for detecting a vision defect in a subject. The method comprises displaying a non-uniform background on a display screen; displaying a visual search target superimposed on the background; receiving eye tracking data related to movement of an eye of the subject viewing the display screen and locating the visual search target; determine an eye movement parameter relating to the received eye tracking data, wherein the eye movement parameter relates to a number of fixations taken to locate the visual search target; comparing the eye movement parameter with a predetermined threshold; and upon determining that the eye movement parameter exceeds the threshold, determining that the subject has a vision defect.
A61B 3/024 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for determining the visual field, e.g. perimeter types
A61B 3/113 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining or recording eye movement
G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer
97.
COMPOUNDS AND METHODS FOR THE DIAGNOSIS, IMAGING AND TREATMENT OF NEURODEGENERATIVE DISEASES AND DISORDERS
THE FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH (Australia)
Inventor
Mccoll, Gawain
Simpson, David, Allan
Hall, Liam, Terres
Grant, Erin, Susanne
Abstract
A method for determining one or more properties of a molecular metal ligand in a sample comprises the steps of: providing a quantum sensor; exposing the quantum sensor to the sample; applying an illumination signal to the quantum sensor for a first predetermined duration; and detecting a photoluminescence intensity emitted from the quantum sensor. A characteristic of the detected photoluminescence intensity is indicative of one of the properties of the molecular metal ligand in the sample.
G01R 33/32 - Excitation or detection systems, e.g. using radiofrequency signals
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
G01N 33/90 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving iron binding capacity of blood
C03B 29/04 - Reheating glass products for softening or fusing their surfacesFire-polishingFusing of margins in a continuous way
B82Y 15/00 - Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
G01N 24/10 - Investigating or analysing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using electron paramagnetic resonance
H01L 29/16 - Semiconductor bodies characterised by the materials of which they are formed including, apart from doping materials or other impurities, only elements of Group IV of the Periodic System in uncombined form
According to an aspect of the present invention, there is provided a face mask, comprising: a frame defining a respiratory chamber, for receiving nose and mouth portions of a user, between a proximal end of the frame for interfacing with a face portion of the user and a distal end of the frame configured for allowing gas exchange with the environment; a vocal guide defined by a sectional portion of the frame, the guide comprising an arched nose ridge portion, side wall portions extending from the nose ridge portion and a base connecting the side wall portions, wherein the guide is configured with an inwardly-projecting contour located at one or more regions of each of the side wall portions so as to alter an output frequency response of sound waves travelling through the frame for improving speech intelligibility of the mask during use.
22 sequestration in subterranean reservoirs may be improved. In one aspect there is provided a method of forming a subterranean silica-gel flow diverter in a carbon sequestration reservoir, the method comprising a step of: (a) co-injecting an acidic solution and an alkali metal silicate solution at a first depth below a first storage volume of the reservoir, such that the solutions mix while distributing laterally; or (b) mixing an acidic solution and an alkali metal silicate solution and injecting resulting mixed solution at a first depth below a first storage volume of the reservoir, such that the mixed solution distributes laterally; wherein silica-gel forms as the co-injected solutions mix or from the mixed solution to provide said flow diverter, which is configured such that at least some of carbon dioxide injected at a depth below said flow diverter is directed laterally within the reservoir before entering the first storage volume. The invention also relates to a subterranean silica-gel flow diverter that may be formed in this manner.
